Stocks of Predictive Oncology Inc. (NASDAQ:POAI) traded higher last session on Wall Street, down -4.83% to $0.41.
According to the data, Predictive Oncology Inc. (NASDAQ:POAI) has 1 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $5.00, we find $5.00. Given the previous closing price of $0.43, this indicates a potential upside of 1062.79 percent. POAI stock price is now -5.25% away from the 50-day moving average and 4.98% away from the 200-day moving average. The market capitalization of the company currently stands at $31.84M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
A total of 0 analysts have issued a hold rating and 1 have given it a buy rating. Brokers who have rated the stock have averaged $5.00 as their price target over the next twelve months.
In other news, HANDLEY DANIEL E, Director bought 6,000 shares of the company’s stock on Dec 15. The stock was bought for $2,460 at an average price of $0.41. Upon completion of the transaction, the Director now directly owns 120,513 shares in the company, valued at $49410.33. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 02, CHIEF FINANCIAL OFFICER MYERS ROBERT L bought 8,795 shares of the business’s stock. A total of $5,001 was incurred on buying the stock at an average price of $0.57. This leaves the insider owning 71,265 shares of the company worth $29218.65. Insiders disposed of 10,199 shares of company stock worth roughly $4181.59 over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in POAI stock. A new stake in Predictive Oncology Inc. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $35,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $18,000 in shares of POAI during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Predictive Oncology Inc. valued at approximately $9,000. MONEY CONCEPTS CAPITAL CORP acquired a new stake in POAI for approximately $6,000. HRT FINANCIAL LP purchased a new stake in POAI valued at around $5,000 in the second quarter. In total, there are 28 active investors with 5.70% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $0.4384 for Predictive Oncology Inc. (NASDAQ: POAI). During the past 12 months, Predictive Oncology Inc. has had a low of $0.21 and a high of $1.10. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.70, and a quick ratio of 7.60. The fifty day moving average price for POAI is $0.4338 and a two-hundred day moving average price translates $0.3911 for the stock.
The latest earnings results from Predictive Oncology Inc. (NASDAQ: POAI) was released for Sep, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.05, missing analysts’ expectations of -$0.04 by -0.01. This compares to -$0.08 EPS in the same period last year. The company reported revenue of $0.46 million for the quarter, compared to $0.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 45.22 percent. For the current quarter, analysts expect POAI to generate $372k in revenue.
Predictive Oncology Inc.(POAI) Company Profile
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Leave a Reply